Literature DB >> 12010799

A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C-catalyzed inactivation.

Keiji Nogami1, Midori Shima, Katsumi Nishiya, Kazuya Hosokawa, Evgueni L Saenko, Yoshihiko Sakurai, Masaru Shibata, Hiroshi Suzuki, Ichiro Tanaka, Akira Yoshioka.   

Abstract

The protective effect of von Willebrand factor (VWF) toward activated protein C (APC)-catalyzed inactivation of factor VIII (FVIII) has been attributed mainly to inhibition of FVIII binding to phospholipid. In the present study, we demonstrated that VWF-mediated FVIII protection from APC also results from direct inhibition of FVIII binding to APC. Inhibition of FVIII binding to anhydro-APC by VWF would be consistent with partial or complete overlap of the FVIII binding sites for APC and VWF. We examined, therefore, the inhibitory effects of 6 synthetic peptides spanning residues 1996 to 2028 around the previously localized APC binding region (FVIII residues 2009-2018). Peptide 2009 to 2018 inhibited FVIII binding to anhydro-APC by 83% (50% inhibition, 55 microM). Similarly, peptide 2013 to 2022 inhibited FVIII binding to VWF by 84% (50% inhibition, 25 microM). It was also found that peptides 2009 to 2018 and 2013 to 2022 optimally bound to anhydro-APC and VWF, respectively. A rabbit antipeptide IgG, raised against peptide 2009 to 2022, blocked the binding of both anhydro-APC and VWF to FVIII. This immunoglobulin G inhibited proteolytic cleavage of FVIII by APC. Our results indicate that the essential regions for the binding of APC and VWF to FVIII overlap and that the protective effect of VWF on APC-catalyzed FVIII inactivation includes competitive inhibition of APC binding to FVIII by VWF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010799     DOI: 10.1182/blood.v99.11.3993

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Highly conserved antigenic structure of the factor VIII C2 domain in some mammals.

Authors:  Jun-ichi Ori; Ichiro Tanaka; Yoko Kubota; Midori Shima; Tomoko Matsumoto; Koichi Yoshida; Yoshihiko Sakurai; Akira Yoshioka
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

2.  The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.

Authors:  Q Shi; J A Schroeder; E L Kuether; R R Montgomery
Journal:  J Thromb Haemost       Date:  2015-06-11       Impact factor: 5.824

3.  Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain.

Authors:  Keiji Nogami; Midori Shima; John C Giddings; Masahiro Takeyama; Ichiro Tanaka; Akira Yoshioka
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

Review 4.  Characterization of factor VIII inhibitors.

Authors:  Midori Shima
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

Review 5.  Factor VIII structure and function.

Authors:  Philip J Fay
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

6.  Identification of extant vertebrate Myxine glutinosa VWF: evolutionary conservation of primary hemostasis.

Authors:  Marianne A Grant; David L Beeler; Katherine C Spokes; Junmei Chen; Harita Dharaneeswaran; Tracey E Sciuto; Ann M Dvorak; Gianluca Interlandi; José A Lopez; William C Aird
Journal:  Blood       Date:  2017-09-12       Impact factor: 22.113

7.  Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report.

Authors:  Masahiro Takeyama; Keiji Nogami; Ryohei Kobayashi; Kenichi Ogiwara; Akira Taniguchi; Yasuaki Nakanishi; Yusuke Inagaki; Yasuhito Tanaka; Midori Shima
Journal:  Int J Hematol       Date:  2018-01-30       Impact factor: 2.490

8.  A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes.

Authors:  Suryasarathi Dasgupta; Ana-Maria Navarrete; Jagadeesh Bayry; Sandrine Delignat; Bharath Wootla; Sébastien André; Olivier Christophe; Michelina Nascimbeni; Marc Jacquemin; Luisa Martinez-Pomares; Teunis B H Geijtenbeek; Arnaud Moris; Jean-Marie Saint-Remy; Michel D Kazatchkine; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-14       Impact factor: 11.205

Review 9.  Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.

Authors:  Marcus Stockschlaeder; Reinhard Schneppenheim; Ulrich Budde
Journal:  Blood Coagul Fibrinolysis       Date:  2014-04       Impact factor: 1.276

10.  Blood Clotting Factor VIII: From Evolution to Therapy.

Authors:  N A Orlova; S V Kovnir; I I Vorobiev; A G Gabibov; A I Vorobiev
Journal:  Acta Naturae       Date:  2013-04       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.